Mozavaptan HydrochlorideCAS: 138470-70-9
MF: C27H29N3O2•HCl
MW: 464.00
A vasopressin V2 selective antagonist.

Mozavaptan Hydrochloride (CAS 138470-70-9)

Mozavaptan Hydrochloride | CAS 138470-70-9 is rated 5.0 out of 5 by 1.
  • y_2020, m_1, d_23, h_13
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_358376, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 133ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: N-[4-[5-(dimethylamino)-2,3,4, 5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide hydrochloride; OPC 31260 hydrochloride
Application: A vasopressin V2 selective antagonist
CAS Number: 138470-70-9
Molecular Weight: 464.00
Molecular Formula: C27H29N3O2•HCl
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Mozavaptan Hydrochloride is a AVP Receptor V2 (vasopressin V2) selective antagonist.

Physical State :
Solid
Solubility :
Soluble in water, and DMSO (≥15 mg/mL ).
Storage :
Store at 4° C
Boiling Point :
543° C at 760 mmHg (Predicted)
Refractive Index :
n20D 1.65 (Predicted)
IC50 :
Vasopressin V2 receptor: IC50 = 12 nM (rat); Vasopressin V2 receptor: IC50 = 500 nM (human)
Ki Data :
Vasopressin V2 recepto: Ki= 9.42 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
636389
MDL Number :
MFCD11111965
SMILES :
CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Mozavaptan Hydrochloride  Product Citations

See how others have used Mozavaptan Hydrochloride. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 27568834  Yamazaki, T. et al. 2016. Eur. J. Pharmacol. 791: 72-77.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 113ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Meijer Meijer, E. et al. (PubMed 21393612) attempted to determine the optimal timing and dosing of the vasopressin V2 receptor antagonist, Mozavaptan, in a mouse model for autosomal dominant polycystic kidney disease. They found that intervention with Mozavaptan should be instituted early on and that it might be necessary to increase the dosage over time. -SCBT Publication Review
Date published: 2015-01-14
  • y_2020, m_1, d_23, h_13
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_358376, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 19ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.